AzureCell Therapies Raises €154K From Venture Kick

Parkinson’s affects over 10 million people globally, and current treatments only manage symptoms without addressing the disease’s root cause—neurodegeneration.

AzureCell aims to change that by developing lab-grown neurons from healthy donor stem cells that can safely replace lost dopamine-producing cells in the brain.

Their technology focuses on solving key challenges like tumor risk, scalability, and long-term effectiveness. With its proprietary cell and genetic engineering platforms, AzureCell ensures the safe and consistent production of high-quality therapeutic neurons.

Read Also - Aim Secures €300K To Fight Information Overload With AI-Powered Briefings

The company is led by experienced founders: CEO Dr. Bilal Fares, a serial biotech entrepreneur; CSO Prof. Karl-Heinz Krause, a stem cell expert with two exits; and SAB Chair Prof. Emi Nagoshi, a specialist in genetic engineering and Parkinson’s research.

AzureCell’s goal is to deliver long-lasting, disease-modifying benefits through next-generation cell-based therapies.

“We started with an ambitious vision to reshape cell therapy for neurodegenerative diseases. Thanks to Venture Kick’s timely funding, clear feedback and strong network, we’ve grown into a team of five with over CHF 1 million in funding and are preparing for incorporation,” highlights CEO Bilal Fares.

The funding will help AzureCell enhance its production platform, transition to GMP standards, and set up key business operations, including branding and IT infrastructure.

About AzureCell Therapies

AzureCell is a biotech spin-off from the University of Geneva developing regenerative cell therapies for Parkinson’s and neurodegenerative diseases. Using advanced stem cell and genetic engineering technologies, AzureCell creates safe, scalable treatments that target the root cause of neurodegeneration—not just the symptoms.